The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AGN-PC-00JWQM     3-propanoyloxy-4- trimethylammonio-butanoate

Synonyms: CHEMBL2074916, CHEBI:28867, HMDB00824, HSDB 7589, CTK8D5864, ...
This record was replaced with 107739.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of (3-carboxy-2-propionyloxy-propyl)-trimethyl-ammonium


Psychiatry related information on (3-carboxy-2-propionyloxy-propyl)-trimethyl-ammonium


High impact information on (3-carboxy-2-propionyloxy-propyl)-trimethyl-ammonium


Chemical compound and disease context of (3-carboxy-2-propionyloxy-propyl)-trimethyl-ammonium


Biological context of (3-carboxy-2-propionyloxy-propyl)-trimethyl-ammonium


Anatomical context of (3-carboxy-2-propionyloxy-propyl)-trimethyl-ammonium


Associations of (3-carboxy-2-propionyloxy-propyl)-trimethyl-ammonium with other chemical compounds


Gene context of (3-carboxy-2-propionyloxy-propyl)-trimethyl-ammonium


Analytical, diagnostic and therapeutic context of (3-carboxy-2-propionyloxy-propyl)-trimethyl-ammonium


  1. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Brevetti, G., Perna, S., Sabbá, C., Martone, V.D., Condorelli, M. J. Am. Coll. Cardiol. (1995) [Pubmed]
  2. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Brevetti, G., Perna, S., Sabbà, C., Rossini, A., Scotto di Uccio, V., Berardi, E., Godi, L. Eur. Heart J. (1992) [Pubmed]
  3. Efficacy of L-propionylcarnitine treatment in patients with left ventricular dysfunction. Caponnetto, S., Canale, C., Masperone, M.A., Terracchini, V., Valentini, G., Brunelli, C. Eur. Heart J. (1994) [Pubmed]
  4. Control of the cardiac consequences of myocardial ischemia and reperfusion by L-propionylcarnitine: age-response and dose-response studies in the rat heart. Riva, E., Leopaldi, D. Pediatr. Res. (1993) [Pubmed]
  5. Lack of correlation between the antiarrhythmic effect of L-propionylcarnitine on reoxygenation-induced arrhythmias and its electrophysiological properties. Barbieri, M., Carbonin, P.U., Cerbai, E., Gambassi, G., Lo Giudice, P., Masini, I., Mugelli, A., Pahor, M. Br. J. Pharmacol. (1991) [Pubmed]
  6. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Vermeulen, R.C., Scholte, H.R. Psychosomatic medicine. (2004) [Pubmed]
  7. L-carnitine enhances excretion of propionyl coenzyme A as propionylcarnitine in propionic acidemia. Roe, C.R., Millington, D.S., Maltby, D.A., Bohan, T.P., Hoppel, C.L. J. Clin. Invest. (1984) [Pubmed]
  8. Metabolic effects of propionate, hexanoate and propionylcarnitine in normoxia, ischaemia and reperfusion. Does an anaplerotic substrate protect the ischaemic myocardium? Sundqvist, K.E., Vuorinen, K.H., Peuhkurinen, K.J., Hassinen, I.E. Eur. Heart J. (1994) [Pubmed]
  9. Differences between carnitine derivatives and coenzyme Q10 in preventing in vitro doxorubicin-related cardiac damages. Neri, B., Neri, G.C., Bandinelli, M. Oncology (1988) [Pubmed]
  10. Thrombosis induced by endothelin (ET-1) and carrageenin in rats treated with indomethacin and propionyl carnitine. Bertelli, A., Bertelli, A.A., Galmozzi, G., Giovannini, L., Mian, M. Drugs under experimental and clinical research. (1993) [Pubmed]
  11. Adenosine and chronic ischemia of the lower limbs. Pasini, F.L., Capecchi, P.L., Perri, T.D. Vascular medicine (London, England) (2000) [Pubmed]
  12. Protection of the ischaemic myocardium by L-propionylcarnitine: effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport, and fatty acid oxidation. Paulson, D.J., Traxler, J., Schmidt, M., Noonan, J., Shug, A.L. Cardiovasc. Res. (1986) [Pubmed]
  13. Effect of propionyl carnitine on cardiac energy metabolism evaluated by the release of purine catabolites. Bertelli, A., Conte, A., Ronca, G., Zucchi, R. Drugs under experimental and clinical research. (1991) [Pubmed]
  14. Electrophysiologic effects of a short-chain acyl carnitine, L-propionylcarnitine, on isolated canine Purkinje fibers. Aomine, M., Nobe, S., Arita, M. J. Cardiovasc. Pharmacol. (1989) [Pubmed]
  15. L-propionylcarnitine and myocardial performance in stunned porcine myocardium. Sassen, L.M., Duncker, D.J., Hogendoorn, A., McFalls, E.O., Krams, R., Bezstarosti, K., Lamers, J.M., Verdouw, P.D. Mol. Cell. Biochem. (1992) [Pubmed]
  16. Effect of carnitine on propionate metabolism in the vitamin B-12--deficient rat. Brass, E.P., Ruff, L.J. J. Nutr. (1989) [Pubmed]
  17. Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Bartels, G.L., Remme, W.J., Pillay, M., Schönfeld, D.H., Kruijssen, D.A. Am. J. Cardiol. (1994) [Pubmed]
  18. Effect of a single IV administration of l-propionylcarnitine on myocardial microcirculation assessed by coronary flow velocity reserve measurement in patients with systemic sclerosis: A pilot study. Montisci, R., Ruscazio, M., Lai, S., Vacca, A., Cauli, A., Passiu, G., Montisci, M., Meloni, L., Mathieu, A., Iliceto, S. Clinical therapeutics (2007) [Pubmed]
  19. Inhibition of oxidative metabolism by propionic acid and its reversal by carnitine in isolated rat hepatocytes. Brass, E.P., Fennessey, P.V., Miller, L.V. Biochem. J. (1986) [Pubmed]
  20. Protection of the reperfused heart by L-propionylcarnitine. Leipälä, J.A., Bhatnagar, R., Pineda, E., Najibi, S., Massoumi, K., Packer, L. J. Appl. Physiol. (1991) [Pubmed]
  21. Methylmalonic semialdehyde dehydrogenase deficiency: psychomotor delay and methylmalonic aciduria without metabolic decompensation. Roe, C.R., Struys, E., Kok, R.M., Roe, D.S., Harris, R.A., Jakobs, C. Mol. Genet. Metab. (1998) [Pubmed]
  22. Protective role of carnitine esters against alcohol-induced gastric lesions in rats. Arafa, H.M., Sayed-Ahmed, M.M. Pharmacol. Res. (2003) [Pubmed]
  23. Complete beta-oxidation of valproate: cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase. Silva, M.F., Ruiter, J.P., Overmars, H., Bootsma, A.H., van Gennip, A.H., Jakobs, C., Duran, M., Tavares de Almeida, I., Wanders, R.J. Biochem. J. (2002) [Pubmed]
  24. L -propionyl-carnitine as superoxide scavenger, antioxidant, and DNA cleavage protector. Vanella, A., Russo, A., Acquaviva, R., Campisi, A., Di Giacomo, C., Sorrenti, V., Barcellona, M.L. Cell Biol. Toxicol. (2000) [Pubmed]
  25. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Mancini, M., Rengo, F., Lingetti, M., Sorrentino, G.P., Nolfe, G. Arzneimittel-Forschung. (1992) [Pubmed]
  26. Enantio- and chemo-selective HPLC separations by chiral-achiral tandem-columns approach: the combination of CHIROBIOTIC TAG and SCX columns for the analysis of propionyl carnitine and related impurities. D'Acquarica, I., Gasparrini, F., Giannoli, B., Badaloni, E., Galletti, B., Giorgi, F., Tinti, M.O., Vigevani, A. Journal of chromatography. A. (2004) [Pubmed]
  27. Interactions of propionate and carnitine metabolism in isolated rat hepatocytes. Brass, E.P., Beyerinck, R.A. Metab. Clin. Exp. (1987) [Pubmed]
  28. Additional antiischemic effects of long-term L-propionylcarnitine in anginal patients treated with conventional antianginal therapy. Bartels, G.L., Remme, W.J., den Hartog, F.R., Wielenga, R.P., Kruijssen, D.A. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. (1995) [Pubmed]
  29. Inhibition of histamine release and pressure increase induced by endothelin (ET-1) in isolated rat kidneys treated with propionyl carnitine. Bertelli, A., Giovannini, L., Bertelli, A.A. Drugs under experimental and clinical research. (1992) [Pubmed]
WikiGenes - Universities